Analyzing and modeling massive transfusion strategies and the role of fibrinogen—How much is the patient actually receiving?
Transfusion · 2024
DOI: 10.1111/trf.17774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Nadia M Keltner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cerus Corporation, Concord, California, USA. Hauptthemen laut MEDLINE: Blood Transfusion, Fibrinogen, Hemorrhage. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Hemorrhage is a leading cause of preventable death in trauma, cardiac surgery, liver transplant, and childbirth. While emphasis on protocolization and ratio of blood product transfusion improves ability to treat hemorrhage rapidly, tools to facilitate understanding of the overall content of a specific transfusion strategy are lacking. Medical modeling can provide insights into where deficits in treatment could arise and key areas for clinical study. By using a transfusion model to gain insight into the aggregate content of massive transfusion protocols (MTPs), clinicians can optimize protocols and create opportunities for future studies of precision transfusion medicine in hemorrhage treatment.
Methods
The transfusion model describes the individual round and aggregate content provided by four rounds of MTP, illustrating that the total content of blood elements and coagulation factor changes over time, independent of the patient's condition. The configurable model calculates the aggregate hematocrit, platelet concentration, percent volume plasma, total grams and concentration of citrate, percent volume anticoagulant and additive solution, and concentration of clotting factors: fibrinogen, factor XIII, factor VIII, and von Willebrand factor, provided by the MTP strategy.
Results
Transfusion strategies based on a 1:1:1 or whole blood foundation provide between 13.7 and 17.2 L of blood products over four rounds. Content of strategies varies widely across all measurements based on base strategy and addition of concentrated sources of fibrinogen and other key clotting factors.
Discussion
Differences observed between modeled transfusion strategies provide key insights into potential opportunities to provide patients with precision transfusion strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cerus Corporation, Concord, California, USA.
- Department of Pathology and Laboratory Medicine and Department of Anesthesiology, Weill Cornell Medicine, New York, New York, USA.
- Department of Anesthesiology, University of Florida, College of Medicine, Gainesville, Florida, USA.
- Department of Surgery and Critical Care Medicine, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Nadia M Keltner, Melissa M Cushing, Philip C Spinella
Zitieren
APA
Keltner, N. M., Cushing, M. M., Haas, T., & Spinella, P. C. (2024). Analyzing and modeling massive transfusion strategies and the role of fibrinogen—How much is the patient actually receiving?. Transfusion. https://doi.org/10.1111/trf.17774
Vancouver
Keltner NM, Cushing MM, Haas T, Spinella PC. Analyzing and modeling massive transfusion strategies and the role of fibrinogen—How much is the patient actually receiving?. Transfusion. 2024. doi:10.1111/trf.17774
BibTeX
@article{Keltner2024,
author = {Keltner, Nadia M and Cushing, Melissa M and Haas, Thorsten and Spinella, Philip C},
title = {Analyzing and modeling massive transfusion strategies and the role of fibrinogen—How much is the patient actually receiving?},
journal = {Transfusion},
year = {2024},
doi = {10.1111/trf.17774}
}
EUVIMED